The identification of woman with a rare gene mutation that results in astoundingly low LDL, or “bad,” cholesterol levels has set off one of the greatest medical chases ever. It is a fevered race among three pharmaceutical companies, Amgen, Pfizer and Sanofi, to test and win approval for a drug that mimics the effects of the mutation, drives LDL levels to new lows and prevents heart attacks. All three companies have drugs in clinical trials and report that their results, so far, are exciting.
Read the full article here: Rare Mutation Ignites Race for Cholesterol Drug